MARKSANS2024-07-012024-09-30 MARKSANS2024-07-012024-09-30 MARKSANS2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member MARKSANS2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member MARKSANS2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524404 MARKSANS NOTLISTED Marksans Pharma Limited Equity 2024-04-01 2025-03-31 2024-11-12 2024-10-23 INR Millions Half yearly 11:40:00 12:21:00 2024-11-12 2024-11-12 true Cash Flow Indirect Not applicable Single segment Manufacturing & Marketing of Pharmaceutical Formulations 2024-07-01 2024-09-30 Unaudited Standalone 3086250000.00 313570000.00 3399820000.00 1347280000.00 309700000.00 -5460000.00 239120000.00 2760000.00 70160000.00 672890000.00 2636450000.00 763370000.00 0.00 763370000.00 126110000.00 5220000.00 131330000.00 0.00 632040000.00 0.00 0.00 0.00 0.00 632040000.00 700000.00 632740000.00 632740000.00 0.00 453160000.00 1 1.39 1.39 0.00 0.00 1.39 1.39 1. The unaudited standalone financial results for the quarter and half year ended 30 September 2024 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 12 November 2024. The Statutory Auditors of the Company have carried out limited review on the above results in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation'), as amended and expressed an unmodified conclusion. 2. The unaudited standalone financial results of the Company have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India and in terms of the Regulation. 3. The Company operates in one reportable business segment namely 'Pharmaceuticals' as per Ind AS 108 on 'Operating Segments'. 4. The above unaudited standalone financials results of the Company are available on the Company's and stock exchanges websites (www.marksanspharma.com), BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed. Single segment 2024-04-01 2024-09-30 Unaudited Standalone 5631520000.00 395090000.00 6026610000.00 2508440000.00 619630000.00 -72350000.00 471050000.00 5590000.00 138520000.00 1169370000.00 4840250000.00 1186360000.00 0.00 1186360000.00 229690000.00 4480000.00 234170000.00 0.00 952190000.00 0.00 0.00 0.00 0.00 952190000.00 1410000.00 953600000.00 953600000.00 0.00 453160000.00 1 2.10 2.10 0.00 0.00 2.10 2.10 Other expenses 672890000.00 Other expenses 1169370000.00 3052340000.00 0.00 0.00 27120000.00 2657530000.00 0.00 332620000.00 2990150000.00 11110000.00 6080720000.00 1646440000.00 153940000.00 5032230000.00 294780000.00 2756700000.00 0.00 403740000.00 8641390000.00 10287830000.00 16368550000.00 453160000.00 12455610000.00 12908770000.00 12908770000.00 0.00 83350000.00 83350000.00 42110000.00 99070000.00 224530000.00 0.00 1673180000.00 502500000.00 2175680000.00 908090000.00 18460000.00 133020000.00 3235250000.00 3459780000.00 16368550000.00 5590000.00 262050000.00 -1392920000.00 0.00 58330000.00 -3400000.00 360000.00 -280000.00 0.00 69460000.00 0.00 -13900000.00 0.00 138520000.00 0.00 800000.00 -2540000.00 256190000.00 0.00 25500000.00 263690000.00 104930000.00 0.00 105010000.00 0.00 -820000.00 0.00 43500000.00 0.00 -817170000.00 369190000.00 0.00 0.00 0.00 145890000.00 0.00 223300000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 600000.00 506260000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 263690000.00 111120000.00 0.00 70160000.00 0.00 -60690000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15230000.00 271900000.00 0.00 0.00 0.00 -287130000.00 -124520000.00 0.00 -124520000.00 419290000.00 294770000.00 940000.00 1890000.00 240000.00 480000.00